AQST - アクエスティブ・セラピュ―ティクス （Aquestive Therapeutics Inc.）

WARREN, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and outlined key 2023 objectives. In addition, Aquestive’s Chief Executive Officer, Daniel Barber, and Chief Financial Officer, Ernie Toth, will host investor meetings from January 9 to 11, 2023 in San Francisco, concurrent with the 41st Annual J. P. Morgan Healthcare Conference.

WARREN, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced the completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (“FDA”) for AQST-109 (epinephrine sublingual film) for the treatment of severe allergic reactions including anaphylaxis.

Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray

Aquestive Therapeutics has been making deals to generate cash to help develop of their epinephrine candidate, AQST-109. See why AQST stock is a Buy.

Aquestive Therapeutics Inc. (NASDAQ:AQST) closed Wednesday at $0.93 per share, up from $0.90 a day earlier. While Aquestive Therapeutics Inc. has overperformed by 2.72%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AQST fell by -84.49%, with highs and lows ranging from $6.40 to $0.62, whereas […]

Aquestive Therapeutics shares have lost two-thirds of their value this year. Read why AQST stock is uninvestable for me at the present.

After 8 months of waiting for an update from the FDA, the agency finally announced a tentative approval for Aquestive''s Libervant. Unfortunately, the company cannot market the product.

WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients'' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the two upcoming investor conferences in September as follows:

Aquestive Therapeutics (AQST), a company focused on different formulations of drugs announced Wednesday that the FDA granted tentative approval for Libervant (diazepam) Buccal Film…

WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients'' problems with current standards of care and provide transformative products to improve their lives, announced today that the U.S. Food & Drug Administration (FDA) has granted tentative approval for Libervant™ (diazepam) Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity ( i.e. , seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

In the last trading session, 1.14 million Aquestive Therapeutics Inc. (NASDAQ:AQST) shares changed hands as the companys beta touched 3.47. With the companys per share price at $4.84 changed hands at -$0.54 or -10.04% during last session, the market valuation stood at $216.11M. AQSTs last price was a discount, traded about -66.53% off its 52-week Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Forecast For 2021: Bullish Signs Point To $28.00 Per Share Read More »

Squarepoint Ops LLC acquired a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,824 shares of the companys stock, valued at approximately $79,000. Squarepoint Ops LLC owned approximately 0.05% of Aquestive []

During the last session, Aquestive Therapeutics Inc. (NASDAQ:AQST)s traded shares were 0.6 million, with the beta value of the company hitting 3.51. At the end of the trading day, the stocks price was $6.24, reflecting an intraday gain of 4.17% or $0.25. The 52-week high for the AQST share is $8.06, that puts it down Aquestive Therapeutics Inc. (NASDAQ: AQST) Stock Jumped 26.06% Over A Month Are There Any Chances Of Growth? Read More »

Brokerages expect that Aquestive Therapeutics, Inc. (NASDAQ:AQST) will report earnings per share (EPS) of ($0.37) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Aquestive Therapeutics earnings, with estimates ranging from ($0.42) to ($0.32). Aquestive Therapeutics posted earnings per share of ($0.60) during the same quarter last year, which []

Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a large increase in short interest in October. As of October 29th, there was short interest totalling 1,480,000 shares, an increase of 22.3% from the October 14th total of 1,210,000 shares. Based on an average trading volume of 495,300 shares, the days-to-cover ratio is currently 3.0 days. Hedge funds have […]